📣 VC round data is live. Check it out!

Korro Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Korro Bio and similar public comparables like Pacific Edge, Diaceutics, Insight Molecular, Alpha Teknova and more.

Korro Bio Overview

About Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.


Founded

2014

HQ

United States

Employees

104

Financials (LTM)

Revenue: $5M
EBITDA: ($103M)

EV

$97M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Korro Bio Financials

Korro Bio reported last 12-month revenue of $5M and negative EBITDA of ($103M).

In the same LTM period, Korro Bio generated $5M in gross profit, ($103M) in EBITDA losses, and had net loss of ($102M).

Revenue (LTM)


Korro Bio P&L

In the most recent fiscal year, Korro Bio reported revenue of $6M and EBITDA of ($83M).

Korro Bio is unprofitable as of last fiscal year, with EBITDA margin of (1298%) and net margin of (1832%).

See analyst estimates for Korro Bio
LTMLast FY202320242025202620272028
Revenue$5M$6M—$2M$6M
Gross Profit$5M———$6M
Gross Margin100%———100%
EBITDA($103M)($83M)($81M)($88M)($83M)
EBITDA Margin(2267%)(1298%)—(3890%)(1299%)
EBIT Margin(2325%)(1365%)—(4047%)(1366%)
Net Profit($102M)($117M)($81M)($84M)($117M)
Net Margin(2234%)(1832%)—(3680%)(1834%)

Financial data powered by Morningstar, Inc.

Korro Bio Stock Performance

Korro Bio has current market cap of $169M, and enterprise value of $97M.

Market Cap Evolution


Korro Bio's stock price is $11.68.

Korro Bio share price decreased by 13.2% in the last 30 days, and increased by 2.3% in the last year.

Korro Bio has an EPS (earnings per share) of $-8.13.

See more trading valuation data for Korro Bio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$97M$169M4.3%-13.2%-3.7%2.3%$-8.13

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Korro Bio Valuation Multiples

Korro Bio trades at 21.4x EV/Revenue multiple, and (0.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Korro Bio

EV / Revenue (LTM)


Korro Bio Financial Valuation Multiples

As of May 23, 2026, Korro Bio has market cap of $169M and EV of $97M.

Korro Bio has a P/E ratio of (1.7x).

LTMLast FY202320242025202620272028
EV/Revenue21.4x15.2x—42.9x15.2x
EV/EBITDA(0.9x)(1.2x)(1.2x)(1.1x)(1.2x)
EV/EBIT(0.9x)(1.1x)(1.2x)(1.1x)(1.1x)
EV/Gross Profit21.4x———15.2x
P/E(1.7x)(1.4x)(2.1x)(2.0x)(1.4x)
EV/FCF—(1.2x)(1.3x)(1.2x)(1.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Korro Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Korro Bio Margins & Growth Rates

Korro Bio decreased revenue by 74% and EBITDA by 3% in the last fiscal year.

In the most recent fiscal year, Korro Bio reported EBITDA margin of (1298%) and net margin of (1832%).

See estimated margins and future growth rates for Korro Bio

Korro Bio Margins

Last FY202420252026202720282029
Gross Margin——100%100%
EBITDA Margin(1298%)(3890%)(1299%)(4814%)
EBIT Margin(1365%)(4047%)(1366%)(4816%)
Net Margin(1832%)(3680%)(1834%)(4617%)
FCF Margin(1236%)(3434%)(1237%)—

Korro Bio Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(74%)—181%(74%)
Gross Profit Growth———(74%)
EBITDA Growth(3%)9%(6%)(3%)
EBIT Growth(8%)9%(5%)(8%)
Net Profit Growth(34%)3%40%(34%)
FCF Growth—4%1%—

Data powered by FactSet, Inc. and Morningstar, Inc.

Korro Bio Operational KPIs

Korro Bio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.

Korro Bio's Rule of 40 is (4888%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Korro Bio's Rule of X is (4999%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Korro Bio
LTMLast FY20242025202620272028
Rule of 40(2336%)(4888%)——
Bessemer Rule of X(2440%)(4999%)——
Revenue per Employee—$0.1M——
Opex per Employee—$0.9M——
G&A Expenses to Revenue624%440%1345%441%
R&D Expenses to Revenue1331%1026%2802%1026%
Opex to Revenue—1465%4147%1466%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Korro Bio Competitors

Korro Bio competitors include Pacific Edge, Diaceutics, Insight Molecular, Alpha Teknova, Vitrafy, Curiosis, Bioventix, Atlantic International, Genomictree and ArcticZymes.

Most Korro Bio public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech, DeepTech and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pacific Edge11.5x19.1x(8.7x)(7.6x)
Diaceutics4.1x3.2x48.1x15.6x
Insight Molecular42.3x51.9x(6.5x)(6.4x)
Alpha Teknova5.4x5.2x(32.5x)(30.2x)
Vitrafy2253.8x88.5x(11.8x)(8.7x)
Curiosis41.9x28.5x(46.3x)(79.1x)
Bioventix6.2x6.4x8.0x8.5x
Atlantic International0.5x0.5x(4.6x)—

This data is available for Pro users. Sign up to see all Korro Bio competitors and their valuation data.

Start Free Trial

Korro Bio Funding History

Before going public, Korro Bio raised $208M in total equity funding, across 2 rounds.

Last private valuation of Korro Bio was $325M, after raising $116M in January 2022 from Eventide.


Korro Bio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-22Series BEventide$116M$325MKorro Bio, a spinout from the Marine Biological Laboratory affiliated with the University of Chicago, develops RNA editing technology to repair mutations causing genetically inherited diseases, with its lead program targeting Alpha-1 Antitrypsin Deficiency (AATD), which leads to liver and lung disease. The company's proprietary OPERAtm platform uses data-driven design, off-the-shelf chemistry, and delivery for highly selective RNA editing, offering gene therapy benefits with transient, repeated dosing for titration of efficacy and safety in a cost-effective format. This positions Korro to expand beyond rare diseases into prevalent conditions across therapeutic areas. In early January 2022, Korro Bio completed a $116 million Series B financing round led by Eventide Asset Management, with participation from new investors including Fidelity Management & Research, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital, and an unnamed healthcare fund, alongside all existing shareholders such as Atlas Venture, New Enterprise Associates (NEA), Wu Capital, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, and Alexandria Venture Investments. This followed a $91.5 million Series A led by Wu Capital in September 2020 and an initial investment from Atlas Venture in 2018. The Series B proceeds fund advancement of the AATD program and pipeline expansion. Joy Ghosh from Eventide and Alex Silverstein from Point72 joined the board post-Series B.
Sep-20Series AAlexandria Venture Investments; Atlas Venture; Cormorant Asset Management; MP Healthcare Venture Management; New Enterprise Associates; Qiming Venture Partners USA; Surveyor Capital; Wu Capital$92M—Korro Bio, a Cambridge, Massachusetts-based RNA therapeutics company, raised $91.5 million in a Series A funding round on September 10, 2020, led by Wu Capital with participation from Atlas Venture, New Enterprise Associates, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management, and Alexandria Venture Investments. The company was founded in 2018 with initial seed funding from Atlas Venture. Korro's proprietary OPERA (Oligonucleotide Promoted Editing of RNA) platform leverages the body's natural ADAR (Adenosine Deaminase Acting on RNA) enzymes for precise, single-base RNA editing to repair disease-causing mutations and create therapeutically beneficial proteins, targeting conditions in the liver, eye, central nervous system, and potentially Parkinson's disease and Duchenne muscular dystrophy. This approach avoids double-stranded DNA breaks unlike conventional gene editing, using endogenous enzymes for targeted, titratable, and reversible therapeutics that are easier to design, manufacture, and deliver. The funding will advance Korro's lead preclinical program toward an investigational new drug (IND) filing and establish a broad portfolio of RNA editing therapies. The technology originated from research by Joshua Rosenthal, Ph.D., a senior scientist at the Marine Biological Laboratory (MBL), affiliated with the University of Chicago. Korro's co-founder and executive chair, Nessan Bermingham, Ph.D., previously led gene editing biotech Intellia Therapeutics and highlighted the platform's potential to usher in a new era of RNA editing therapies. Investors expressed confidence in the proof-of-mechanism demonstrated in animal models for specific and safe single-base RNA editing across debilitating diseases. No financial metrics such as post-money valuation, revenue, ARR, EBITDA, or valuation multiples were disclosed in announcements. Korro Bio remains at the preclinical stage, focusing on platform validation and pipeline expansion without reported commercial traction or financial performance data around the 2020 round.

Korro Bio M&A Activity

Korro Bio has acquired 1 company to date.

Last acquisition by Korro Bio was on July 14th 2023. Korro Bio acquired Frequency Therapeutics for $117M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Korro Bio

Frequency Therapeutics
Description
Frequency Therapeutics is a biotechnology firm developing small-molecule drugs that regenerate auditory sensory cells to treat hearing loss. Its lead candidate FX-322 targets noise-induced and age-related conditions through transient progenitor cell activation. Woburn-headquartered and founded in 2014, the company advanced FX-322 into Phase 2b clinical trials by 2021. Frequency Therapeutics focuses on inner ear therapeutics without cell or gene therapy complexities, with operations in the United States.
HQ CountryUnited States
HQ City
Lexington, KY
Deal Date14 Jul 2023
Valuation$117M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Korro Bio acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Korro Bio

When was Korro Bio founded?Korro Bio was founded in 2014.
Where is Korro Bio headquartered?Korro Bio is headquartered in United States.
How many employees does Korro Bio have?As of today, Korro Bio has over 104 employees.
Who is the CEO of Korro Bio?Korro Bio's CEO is Ram Aiyar.
Is Korro Bio publicly listed?Yes, Korro Bio is a public company listed on Nasdaq.
What is the stock symbol of Korro Bio?Korro Bio trades under KRRO ticker.
When did Korro Bio go public?Korro Bio went public in 2023.
Who are competitors of Korro Bio?Korro Bio main competitors include Pacific Edge, Diaceutics, Insight Molecular, Alpha Teknova, Vitrafy, Curiosis, Bioventix, Atlantic International, Genomictree, ArcticZymes.
What is the current market cap of Korro Bio?Korro Bio's current market cap is $169M.
What is the current revenue of Korro Bio?Korro Bio's last 12 months revenue is $5M.
What is the current revenue growth of Korro Bio?Korro Bio revenue growth (NTM/LTM) is (69%).
What is the current EV/Revenue multiple of Korro Bio?Current revenue multiple of Korro Bio is 21.4x.
Is Korro Bio profitable?No, Korro Bio is not profitable.
What is the current EBITDA of Korro Bio?Korro Bio has negative EBITDA and is not profitable.
What is Korro Bio's EBITDA margin?Korro Bio's last 12 months EBITDA margin is (2267%).
What is the current EV/EBITDA multiple of Korro Bio?Current EBITDA multiple of Korro Bio is (0.9x).
How many companies Korro Bio has acquired to date?As of May 2026, Korro Bio has acquired 1 company.
What was the largest acquisition by Korro Bio?$117M acquisition of Frequency Therapeutics on 14th July 2023 was the largest M&A Korro Bio has done to date.
What companies Korro Bio acquired?Korro Bio acquired Frequency Therapeutics.
In how many companies Korro Bio has invested to date?Korro Bio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Korro Bio

Lists including Korro Bio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial